Business ❯ Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials GLP-1 Drugs Weight Loss Drugs Eli Lilly Acquisitions Oncology Obesity Drugs Obesity Treatments Market Performance Eli Lilly and Company

3 ARTICLES

yesterday

Lilly Pulls Ahead in GLP-1 Race as Markets Sharpen Valuation Split

Lilly’s strong U.S. sales, an oral GLP-1 launch and growing hedge-fund holdings have pushed its valuation higher and signaled investor confidence in its commercial momentum.

23 ARTICLES

4d ago

Lilly Sues Six U.S. Firms Over Black‑Market Sales of Experimental Drug Retatrutide

22 ARTICLES

last mo.

AstraZeneca in Talks With Bristol Myers on Potential $400 Billion Merger

7 ARTICLES

last mo.

Pfizer Raises 2026 Revenue Floor After Q2 Beat as Covid Sales Fall

3 ARTICLES

last mo.

Eli Lilly Trades at a High Multiple as GLP‑1 Catalysts Loom

4 ARTICLES

last mo.

Dupixent Surge Lets Sanofi Reset Strategy as Regeneron Posts Strong Quarter

11 ARTICLES

last mo.

Argenx Agrees to Buy Forte Biosciences for $2.2 Billion

7 ARTICLES

2mo ago

GSK Reports Q2 Beat and Unveils £1.9 Billion Savings Plan

10 ARTICLES

2mo ago

Bristol Myers Squibb Buys Second NVIDIA DGX SuperPOD Built on Vera Rubin

6 ARTICLES

2mo ago

Samsung Biologics Launches SFr1.46 Billion Cash Bid for PolyPeptide

10 ARTICLES

2mo ago

Tesla Commits to Major Grünheide Production Ramp and On‑Site Cell Manufacturing

6 ARTICLES

2mo ago

Agenus Secures $85M Now and Up to $340M Total to Back a Registrational Colon Cancer Trial

11 ARTICLES

2mo ago

Drug Development

Lilly Pulls Ahead in GLP-1 Race as Markets Sharpen Valuation Split

Novo Sets Bold 2030 Targets but Shares Slide After Investors Question Pipeline

AbbVie Completes $10.9 Billion Buy of Apogee Therapeutics

Lilly Still Dominates GLP‑1 Market as New Rivals Gain Traction

FDA Places Clinical Hold on REGENXBIO's RGX‑121 After Spine MRI Findings

UK Approves Lilly’s Oral GLP‑1 Pill Foundayo

Capricor Seeks New FDA Path for Duchenne Drug After 9–3 Advisory Vote

AstraZeneca Walks Away From Proposed $400 Billion Bristol Myers Merger

Lilly Sues Six U.S. Firms Over Black‑Market Sales of Experimental Drug Retatrutide

AstraZeneca in Talks With Bristol Myers on Potential $400 Billion Merger

Never miss stories about

Drug Development

Pfizer Raises 2026 Revenue Floor After Q2 Beat as Covid Sales Fall

Eli Lilly Trades at a High Multiple as GLP‑1 Catalysts Loom

Dupixent Surge Lets Sanofi Reset Strategy as Regeneron Posts Strong Quarter

Argenx Agrees to Buy Forte Biosciences for $2.2 Billion

GSK Reports Q2 Beat and Unveils £1.9 Billion Savings Plan

Bristol Myers Squibb Buys Second NVIDIA DGX SuperPOD Built on Vera Rubin

Samsung Biologics Launches SFr1.46 Billion Cash Bid for PolyPeptide

Tesla Commits to Major Grünheide Production Ramp and On‑Site Cell Manufacturing

Agenus Secures $85M Now and Up to $340M Total to Back a Registrational Colon Cancer Trial

Healthcare ETFs Force a Choice Between Low Cost and Higher Growth

Never miss stories about

Drug Development